Efficacy Augmentation of Ferroptosis-Inducing Nanomedicine for Tyrosine Kinase Inhibitor-Resistant Lung Cancer Brain Metastasis
ACS Nano · 2026
DOI: 10.1021/acsnano.6c09281 ↗Kurz gefasst
Fachartikel in der Zeitschrift ACS Nano, 2026. Verfasst von Youming Zeng und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiology, Huadong Hospital, Shanghai Key Laboratory of Clinical Geriatric Medicine, Shanghai Institute of Geriatrics and Gerontology, …. Hauptthemen laut MEDLINE: Ferroptosis, Brain Neoplasms, Lung Neoplasms, Protein Kinase Inhibitors. Die Arbeit nennt 64 Literaturangaben. Gefördert von: Ministry of Science and Technology of the People's Republic of China, National Natural Science Foundation of China (NSFC).
Abstract (Originalsprache)
Acquired resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) poses a major clinical challenge for EGFR-mutant non-small-cell lung cancer patients with brain metastasis. A key unresolved question is whether the adaptive mechanisms driving TKI resistance also confer new therapeutic vulnerabilities. Here, we reveal that TKI-resistant lung cancer brain metastatic cells develop a redox perturbation state, characterized by elevated oxidative stress and diminished antioxidant capacity, which confers a latent sensitivity to ferroptosis induction. To exploit this vulnerability, we developed MIL-S@M, a brain-targeted nanoplatform capable of efficient blood-brain barrier penetration and glutathione-responsive drug release. MIL-S@M potently induces ferroptosis through the synergistic effects of iron overload, glutathione depletion, and glutathione peroxidase 4 inactivation. In mouse models of osimertinib-resistant brain metastasis, MIL-S@M significantly suppressed tumor growth and extended survival, both as a monotherapy and in combination with osimertinib, without inducing systemic or neurotoxic effects. This work unveils a targetable adaptation in TKI-resistant brain metastasis and presents a translatable nanotherapeutic strategy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Radiology, Huadong Hospital, Shanghai Key Laboratory of Clinical Geriatric Medicine, Shanghai Institute of Geriatrics and Gerontology, State Key Laboratory of Brain Function and Disorders, MOE Frontiers Ce…
- Department of Neurosurgery, Huashan Hospital, Institute for Translational Brain Research, Fudan University, Shanghai200032, China.
- National Center for Neurological Disorders, Shanghai Key Laboratory of Brain Function and Restoration and Neural Regeneration, Shanghai Clinical Medical Center of Neurosurgery, Neurosurgical Institute of Fudan Universit…
- National Children's Medical Center, Children's Hospital, Shanghai Key Laboratory of Gene Editing and Cell Therapy for Rare Diseases, Center for Clinical Neuro-AI, Fudan University, Shanghai201102, China.
ORCID-Profile: Haibao Peng, Yudan Chi
Förderung
- Ministry of Science and Technology of the People's Republic of China
- National Natural Science Foundation of China (NSFC)
Zitieren
APA
Zeng, Y., Lin, C., Yang, J., Fu, M., Ma, J., Mo, L., Huang, Y., Li, X., Li, C., Zeng, R., Li, Y., Yang, W., Peng, B., Peng, H., & Chi, Y. (2026). Efficacy Augmentation of Ferroptosis-Inducing Nanomedicine for Tyrosine Kinase Inhibitor-Resistant Lung Cancer Brain Metastasis. ACS Nano. https://doi.org/10.1021/acsnano.6c09281
Vancouver
Zeng Y, Lin C, Yang J, Fu M, Ma J, Mo L, et al. Efficacy Augmentation of Ferroptosis-Inducing Nanomedicine for Tyrosine Kinase Inhibitor-Resistant Lung Cancer Brain Metastasis. ACS Nano. 2026. doi:10.1021/acsnano.6c09281
BibTeX
@article{Zeng2026,
author = {Zeng, Youming and Lin, Chenyu and Yang, Jiahui and Fu, Minjie and Ma, Jiadong and Mo, Lan and Huang, Yang and Li, Xiaohui and Li, Cheng and Zeng, Rui and Li, Yiyang and Yang, Wanqi and Peng, Bo and Peng, Haibao and Chi, Yudan},
title = {Efficacy Augmentation of Ferroptosis-Inducing Nanomedicine for Tyrosine Kinase Inhibitor-Resistant Lung Cancer Brain Metastasis},
journal = {ACS Nano},
year = {2026},
doi = {10.1021/acsnano.6c09281}
}
EUVIMED